Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
To accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
Use the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Natural killer T cells (NKT cells), unlike conventional T cells, specifically recognize self lipid– or foreign lipid–based antigens bound to the monomorphic MHC class I–like molecule CD1d. NKT cells have been linked to microbial immunity, autoimmunity, allergy and cancer and, accordingly, they represent an important immunotherapeutic target with immense clinical potential. Type I NKT cells express a semi-invariant TCR that has an invariant α-chain and a restricted TCRβ repertoire (α-chain variable region 24–α-chain joining region 18 paired with β-chain variable region 11 (Vα24-Jα18-Vβ11) in humans, and Vα14-Jα18 paired with Vβ8, Vβ7 or Vβ2 in mice). Nevertheless, despite this restricted TCR repertoire, NKT cell TCRs bind an array of different CD1d-restricted lipid-based antigens, including phospholipids9, as well as α-linked and β-linked glycolipids. The α-glycosidic linkage that defines α-galactosylceramide (α-GalCer) and other bacteria-derived NKT cell agonists, including α-glycuronosylceramides and α-galactosyldiacylglycerols, is considered to represent a 'microbial signature', as glycolipid antigens in mammals are typically β-linked anomers. The structures of NKT cell TCRs in complex with many α-linked glycolipids have been determined, including CD1d–α-GalCer and variants thereof and α-galactosyldiacylglycerol. Although the NKT cell TCR has been shown to be relatively rigid, conformational adjustments in complexes of CD1d and α-linked antigen permit optimal engagement of NKT cell TCRs. That is, a conserved docking topology is observed whereby the NKT cell TCR shows a parallel docking mode above the F′ pocket of the CD1d antigen-binding cleft, whereas the α-linked glycosyl moiety 'sits' snug and flat against CD1d, making many direct specificity-governing contacts with the NKT cell TCR.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.